Welcome to our dedicated page for Conmed SEC filings (Ticker: CNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CONMED Corporation filings document the regulatory record for a medical technology company with common stock listed on the NYSE under the symbol CNMD. Its Form 8-K reports cover quarterly and annual operating results, investor presentations furnished under Regulation FD, finance leadership changes, and portfolio actions involving gastroenterology products and distribution agreements.
The company’s proxy materials disclose board matters, annual meeting voting, executive compensation, equity awards, and related governance information. CONMED’s filing record also identifies its capital stock structure, including common stock with $0.01 par value, and provides formal exhibits for earnings releases, presentations, transition agreements, and other material corporate updates.
Schabacker Matthew reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation reported an amended Form 4 showing that executive Matthew Schabacker, VP GM Advanced Surgical, received a corrected grant of 17,471 restricted stock units (RSUs) under the company’s 2025 Long-Term Incentive Plan.
Each RSU represents a contingent right to one share of CONMED common stock. The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% in the second year, and 34% in the third year. The amendment clarifies that this total includes a special award of 7,644 RSUs in addition to the originally reported 9,827 RSUs.
Foust Hollie K reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation granted General Counsel and Corporate Secretary Hollie K. Foust 18,563 restricted stock units (RSUs) under its 2025 Long-Term Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs generally vest over three years, with 33% vesting after one year, another 33% in the second year, and 34% in the third year. This Form 4/A amends a prior report to correct the grant amount, noting that a special award of 7,644 RSUs was added to the originally reported 10,919 RSUs to reach the total of 18,563 RSUs.
Ferrell John D. reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation’s Executive Vice President – HR, John D. Ferrell, reported a compensation-related grant of 16,926 restricted stock units (RSUs). The RSUs were awarded under the company’s 2025 Long-Term Incentive Plan and generally vest over three years, with 33% vesting after one year, another 33% after two years, and 34% after three years.
This amended Form 4 corrects the originally reported grant amount by reflecting an additional special award of 7,644 RSUs on top of the previously reported 9,282 RSUs, bringing the total to 16,926 RSUs tied to an equivalent number of common shares.
SHAGORY PETER K reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corporation executive Peter K. Shagory received a corrected equity award totaling 16,926 restricted stock units (RSUs). Each RSU represents a right to receive one share of CONMED common stock under the Company’s 2025 Long-Term Incentive Plan.
The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% in the second year, and 34% in the third year. This Form 4/A amends the prior report to reflect that a special award of 7,644 RSUs was granted in addition to the originally reported 9,282 RSUs, for the total 16,926 RSUs now shown as held directly following the transaction.
CONMED Corporation reported that Andrew Moller, age 51, will become Interim Principal Financial Officer effective March 15, 2026. He currently serves as Vice President, Corporate Controller and has been the Company’s Principal Accounting Officer since April 2025.
Before joining CONMED in January 2025, Moller held senior finance roles at Smith & Nephew, including Global Controller and CFO Asia-Pacific, and previously worked at Stanley Black & Decker. The company states there are no related-party transactions or family relationships involving Moller and its directors, and his compensation arrangements are unchanged with this interim appointment.
CONMED Corp executive Brent Lalomia exercised restricted stock units and received additional common shares as compensation. On March 6, 2026, 75 RSUs converted into 75 shares of common stock, and 26 of those shares were withheld at a price of $39.90 per share to cover tax obligations. After these transactions, Lalomia directly held 915.057 shares of CONMED common stock. A footnote also clarifies that prior reported holdings have been adjusted to exclude 140 shares that were previously reported in error.
Schabacker Matthew reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp reported that executive Matthew Schabacker, VP GM Advanced Surgical, received equity awards consisting of 9,827 restricted stock units and options to purchase 11,646 shares of common stock. The RSUs generally vest over three years, while the stock options generally vest in equal parts over four years.
Ferrell John D. reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp Executive Vice President of HR John D. Ferrell reported equity awards in the form of restricted stock units and stock options. He was granted 9,282 RSUs, each representing one share of common stock, which generally vest over three years in 33%, 33%, and 34% annual installments. He also received options to purchase 10,999 shares of common stock, generally vesting in equal 25% installments over four years under the 2025 Long-Term Incentive Plan.
Pelletier Johonna Marie reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp reported that Treasurer and VP, Tax Johonna Marie Pelletier received a grant of 5,896 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of CONMED common stock under the 2025 Long-Term Incentive Plan.
The RSUs generally vest over three years, with 33% vesting one year after the grant date, another 33% in the second year, and the remaining 34% in the third year, encouraging multi‑year retention and alignment with shareholders.
SHAGORY PETER K reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp granted equity awards to executive Peter K. Shagory, EVP, Strategy & Corporate Development. He received 9,282 RSUs (Restricted Stock Units), each representing one future share of common stock, under the company’s 2025 Long-Term Incentive Plan.
The RSUs generally vest over three years, with 33% vesting after one year, another 33% after two years, and 34% after three years from the March 2, 2026 grant date. He was also granted 10,999 stock options under the same plan, which generally vest in equal 25% installments over four years, starting one year after the grant date.